Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAarif AhsanCMChristine MantisCRCesar Rodriguez

Discussion

Loading...

Member takes

Overview

Correlative biomarker analyses highlight T-cell activation and cytokine release in RRMM, indicating potential benefits of etentamig treatment.

Key Points

  • This research investigates the effects of etentamig on T-cell activity and proinflammatory cytokines in RRMM patients.
  • Correlative biomarker analyses from Phase 1 and Phase 1b clinical trials of etentamig.
  • Blood and serum samples collected from RRMM patients receiving etentamig monotherapy.
  • Flow cytometry and Luminex® used to analyze immune cell populations and cytokines, respectively.
  • Single-cell sequencing performed for T-cell and B-cell receptor analyses.
  • Etentamig treatment increased proinflammatory cytokines and enhanced T-cell activation and proliferation.
  • Cytokine release syndrome was correlated with proinflammatory cytokine levels during treatment cycles.
  • A modified dexamethasone regimen reduced baseline IL-6 levels and CRS incidence.
  • Increased T-cell to myeloma cell ratios at baseline linked to better response to etentamig.

Cite This Study

Ahsan et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7c8https://doi.org/10.1182/blood-2025-2204
View Full Paper
Ask AI
Bookmark
Share